KRASG12C Inhibitor vs Chemotherapy Trial Results: Pooled Analysis of 798 Patients

A meta-analysis of 798 patients from two phase 3 randomized controlled trials (CodeBreaK 200 and KRYSTAL-12) evaluates KRASG12C inhibitors for non-small cell lung cancer. The analysis, authored by Shuang Liang and last updated in April 2026, shows significant improvements in progression-free survival and response rates compared to chemotherapy. The dataset is a 230 KB document containing the pooled results table.

Use Cases

• Compare progression-free survival (PFS) and central nervous system-PFS hazard ratios between treatment groups.
• Analyze objective response rate (ORR) and disease control rate (DCR) improvements from the meta-analysis.
• Evaluate the safety profile of KRASG12C inhibitors based on treatment-related adverse event (TRAE) rates.
• Conduct subgroup analyses to assess the consistency of treatment benefits across patient demographics.

Strengths

• Data is derived from two phase 3 randomized controlled trials, a gold standard for clinical evidence.
• Analysis includes 798 patients, providing a substantial sample for the pooled results.
• Specific efficacy metrics are reported, including hazard ratios for PFS (HR: 0.62) and CNS-PFS (HR: 0.55).
• Adverse event data is detailed, listing the top three grade 3–5 TRAEs with specific incidence percentages.

Limitations

• The dataset is a 230 KB DOC file; the underlying tabular data structure and column definitions are not provided.
• Row count for the original trial data is unknown, limiting assessment of the raw data's scale.
• The data reflects a specific meta-analysis scope; generalizability to other cancer types or treatments is not implied.

Provenance

Source

figshare, authored by Shuang Liang.

Collection Method

Pooled analysis and meta-analysis of two identified phase 3 RCTs (CodeBreaK 200 and KRYSTAL-12).

Freshness

Last updated 2026-04-15 05:47:43.